-
WCLC 2024 | Selected Oral Presentations: Treatment of Pleural Mesothelioma, Thymic Carcinoma, and Undifferentiated Thoracic Tumors
The 2024 World Conference on Lung Cancer is happening in San Diego from September 7th to 10th! The WCLC website has already released important abstracts. Below are some key research…
-
WCLC 2024 | Selected Oral Presentations: Multimodal Treatment of Stage III Lung Cancer
The 2024 World Conference on Lung Cancer is taking place in San Diego from September 7th to 10th! Some key abstracts have already been released. Here’s an overview of the…
-
WCLC 2024 | Selected Oral Presentations: Optimizing the Timing of Supportive Care
1 OA07.03—The Effect of Personalized Music Therapy on Perioperative Pain and Anxiety in NSCLC Patients 2 OA07.04—Optimising Care of Older Patients with Lung Cancer – An Innovative Nurse-led Model of…
-
New Insights on Extended Anticoagulation for Venous Thromboembolism
At ASH 2024, researchers presented findings from the RENOVE trial (NCT03285438), evaluating reduced-dose vs full-dose direct oral anticoagulants for patients at high risk of recurrent venous thromboembolism (VTE). Key Findings:…
-
Dr. Xiaowen Zhai: Clinical Research Progress in Stem Cell Transplantation for Pediatric Monogenic Diseases
Monogenic diseases, a class of hereditary disorders caused by gene mutations, are diverse and have a profound impact. In the pediatric field, stem cell transplantation is emerging as a promising treatment for conditions such as inborn errors of immunity (IEI), very early-onset inflammatory bowel disease (VEO-IBD), and inherited metabolic diseases (IEM). At the 12th Lu…
-
Dr. Zhenyu Li: Application of GPRC5D CAR-T in Relapsed and Refractory Multiple Myeloma
On August 24, 2024, the 12th Lu Daopei Hematology Forum successfully concluded. At the forum, Dr. Zhenyu Li from The Affiliated Hospital of Xuzhou Medical University delivered a compelling presentation titled “GPRC5D CAR-T Therapy for Relapsed and Refractory Multiple Myeloma”. He shared insights into the application of GPRC5D-targeted CAR-T cells and BCMA/GPRC5D dual-target CAR-T cells…
-
NEJM: Dr. Ruihua Xu’s Team Offers a New Targeted Therapy for Advanced Gastric Cancer Patients Worldwide
Gastric cancer is the fifth most common malignancy globally. For advanced gastric cancer, systemic treatments such as chemotherapy and targeted therapies are the primary treatment options. However, HER2-negative advanced gastric cancer patients have long lacked effective targeted drugs. Claudin 18.2 (CLDN18.2) is a tight junction protein, and nearly 40% of patients with HER2-negative gastric cancer…
-
China’s Benchmark, Sharing Global Insights—CSCO BC Experts, Led by Dr. Zefei Jiang, Share “Chinese Wisdom” in Breast Cancer Diagnosis and Treatment
The Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC) has developed the CSCO Breast Cancer Diagnosis and Treatment Guidelines (hereafter referred to as the CSCO BC Guidelines), which have become a crucial reference for Chinese clinicians, serving as a “navigation tool” for clinical decision-making. With the rapid progress of clinical oncology,…
Connecting Medical Expertise through Media